INCYTE REPORTS POSITIVE RESULTS OF JAK INHIBITOR TESTED IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA PATIENTS
MPNRF | December 11, 2010
Incyte Corp. is currently working on phase II clinical trials for their JAK Inhibitor INCB18424. These trials are testing safety and efficacy of this drug, meant to relieve constitutional symptoms in ET and PV patients. Results were reported at the American Society of Hematology’s annual meeting.